SCHEMBL3403519

SCHEMBL3403519

N#CC1CC(F)CN1C(=O)CBr

nearest known ligand 0.62

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 20/20 0.62
FAP Q12884 1/20 0.51
DPP8 Q6V1X1 1/20 0.51
DPP9 Q86TI2 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3783546 1.00 DPP4 (0.62) DPP4FAPDPP8DPP9
SCHEMBL3784767 1.00 DPP4 (0.62) DPP4FAPDPP8DPP9
SCHEMBL3789137 1.00 DPP4 (0.62) DPP4FAPDPP8DPP9
SCHEMBL1154888 1.00 DPP4 (0.62) DPP4FAPDPP8DPP9
SCHEMBL1493788 0.85 DPP4 (0.64) DPP4FAPDPP8DPP9
SCHEMBL23360603 0.83 DPP4 (0.62) DPP4FAPDPP8DPP9
SCHEMBL3828184 0.83 DPP4 (0.62) DPP4FAPDPP8DPP9
SCHEMBL14417777 0.83 DPP4 (0.65) DPP4
SCHEMBL3785926 0.83 DPP4 (0.62) DPP4FAPDPP8DPP9
SCHEMBL16677118 0.83 DPP4 (0.62) DPP4FAPDPP8DPP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2865666-B1 HEXAHYDROPENTALENO DERIVATIVES, PREPARATION METHOD AND USE IN MEDICINE THEREOF SUNSHINE LAKE PHARMA CO LTD (CN) 2017-05-31 EP claimed
US-9567300-B2 Hexahydropentaleno derivatives, preparation method and use in medicine thereof SUNSHINE LAKE PHARMA CO., LTD. (CN) 2017-02-14 US claimed
US-20150299118-A1 HEXAHYDROPENTALENO DERIVATIVES, PREPARATION METHOD AND USE IN MEDICINE THEREOF SUNSHINE LAKE PHARMA CO., LTD. (CN) 2015-10-22 US claimed
EP-2865666-A1 HEXAHYDROPENTALENO DERIVATIVES, PREPARATION METHOD AND USE IN MEDICINE THEREOF Sunshine Lake Pharma Co., Ltd. (CN) 2015-04-29 EP claimed
EP-2865666-B1 HEXAHYDROPENTALENO DERIVATIVES, PREPARATION METHOD AND USE IN MEDICINE THEREOF SUNSHINE LAKE PHARMA CO LTD (CN) 2017-05-31 EP disclosed
US-9567300-B2 Hexahydropentaleno derivatives, preparation method and use in medicine thereof SUNSHINE LAKE PHARMA CO., LTD. (CN) 2017-02-14 US disclosed
US-20150299118-A1 HEXAHYDROPENTALENO DERIVATIVES, PREPARATION METHOD AND USE IN MEDICINE THEREOF SUNSHINE LAKE PHARMA CO., LTD. (CN) 2015-10-22 US disclosed
EP-2865666-A1 HEXAHYDROPENTALENO DERIVATIVES, PREPARATION METHOD AND USE IN MEDICINE THEREOF Sunshine Lake Pharma Co., Ltd. (CN) 2015-04-29 EP disclosed
EP-2252582-A2 PYRROLIDINE DERIVATIVES National Health Research Institutes (TW) 2010-11-24 EP disclosed
WO-2009111239-A2 PYRROLIDINE DERIVATIVES NATIONAL HEALTH RESEARCH INSTITUTES (TW) 2009-09-11 WO disclosed
EP-2035395-A2 NOVEL PROCESSES FOR THE PREPARATION OF DPP IV INHIBITORS Glenmark Pharmaceuticals S.A. (CH) 2009-03-18 EP disclosed
WO-2008001195-A2 NOVEL PROCESSES FOR THE PREPARATION OF DPP IV INHIBITORS GLENMARK PHARMACEUTICALS S.A. (US) 2008-01-03 WO disclosed
EP-1399433-B1 FLUOROPYRROLIDINES AS DIPEPTIDYL PEPTIDASE INHIBITORS SMITHKLINE BEECHAM CORP (US) 2007-08-22 EP disclosed
US-7183290-B2 Fluoropyrrolidines as dipeptidyl peptidase inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2007-02-27 US disclosed
US-20040242636-A1 Enzyme inhibitors as antiinflammatory ageents for psoriasis, obesity SMITHKLINE BEECHAM CORPORATION 2004-12-02 US disclosed
EP-1399433-A2 FLUOROPYRROLIDINES AS DIPEPTIDYL PEPTIDASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2004-03-24 EP disclosed
WO-2003002553-A2 FLUOROPYRROLIDINES AS DIPEPTIDYL PEPTIDASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2003-01-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040242636-A1 Enzyme inhibitors as antiinflammatory ageents for psoriasis, obesity DPP4, DPP7, DPP3 DPP4 1/4885FAP 9/4885DPP8 4/4885
US-20150299118-A1 HEXAHYDROPENTALENO DERIVATIVES, PREPARATION METHOD AND USE IN MEDICINE THEREOF DPP4, DPP7, DPP3 DPP4 1/4885FAP 25/4885DPP8 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.